Dulaglutide biosimilar (Rophibio)

度拉糖肽生物类似药（Rophibio）

Report date: 2024/06/27 11:40:22

Base Information

Drug NameDulaglutide biosimilar (Rophibio)

Drug Alias NameN/A

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionGlucagon-like peptide 1 receptor agonists

TargetsGlucagon-like peptide 1 receptor

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRophibio Inc

China Registration ClassN/A

Active CompaniesRophibio Inc

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

ATC CodeN/A